R&D at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s R&D?
- Monte Rosa Therapeutics, Inc. (GLUE) reported R&D of $44.07M in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s R&D changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s R&D increased by 36.9% year-over-year, from $32.19M to $44.07M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s R&D?
- Over 4 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s R&D has grown at a 25.4% compound annual growth rate (CAGR), from $57.16M to $141.5M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.